In a study led by Robert Abramovitch, from the Michigan State University in the US, the ancient remedy artemisinin stopped the ability of TB-causing bacteria, known as Mycobacterium tuberculosis, to become dormant.
This stage of the disease often makes the use of antibiotics ineffective.
"When TB bacteria are dormant, they become highly tolerant to antibiotics," Abramovitch said.
"Blocking dormancy makes the TB bacteria more sensitive to these drugs and could shorten treatment times," he said.
Mycobacterium tuberculosis, or Mtb, needs oxygen to thrive in the body. The immune system starves this bacterium of oxygen to control the infection.
By disrupting this sensor and essentially turning it off, the artemisinin stopped the disease's ability to sense how much oxygen it was getting.
"When the Mtb is starved of oxygen, it goes into a dormant state, which protects it from the stress of low-oxygen environments," Abramovitch said.
"If Mtb can't sense low oxygen, then it can't become dormant and will die," he said.
Abramovitch indicated that dormant TB can remain inactive for decades in the body. However, if the immune system weakens at some point, it can wake back up and spread.
"Patients often don't stick to the treatment regimen because of the length of time it takes to cure the disease," he said.
"Incomplete therapy plays an important role in the evolution and spread of multi-drug resistant TB strains," he said.
The research could be key to shortening the course of therapy because it can clear out the dormant, hard-to-kill bacteria. This may lead to improving patient outcomes and slowing the evolution of drug-resistant TB.
"TB is a global problem that requires new tools to slow its spread and overcome drug resistance. This new method of targeting dormant bacteria is exciting because it shows us a new way to kill it," said Abramovitch.
The study was published in the journal Nature Chemical Biology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
